endoscopic sinus News
-
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
-
Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you